|
Recent Reviews (Adobe Acrobat Required)
Tuberous Sclerosis: from Tubers to mTOR (Kwiatkowski, '04)
Target of rapamycin (TOR): an integrator of nutrient and growth (Fingar and Blenis, '04)
Metastasis of Benign Tumor Cells in Tuberous Sclerosis Complex (Henske, '03)
Recent TSC pathway articles by Rothberg Courage Award sponsored scientists:
David J. Kwiatkowski-Brigham and Women's Hospital, Harvard Medical School
Perturbed IFN-g -Jak-Signal Transducers
and Activators of Transcription Signaling in Tuberous Sclerosis
Mouse Models: Synergistic Effects of Rapamycin-IFN-g
Treatment (El-Hashemite et al, '04).
Tian Xu-Howard Hughes Medical Institute, Yale University School of Medicine
Akt regulates growth by directly phosphorylating Tsc2 (Potter
et al, '02).
Lewis C. Cantley-Department of Cell Biology, Harvard Medical School
Identification of the Tuberous Sclerosis Complex-2 Tumor Suppressor
Gene Product Tuberin as a Target of the Phosphoinositide 3-Kinase/Akt
Pathway (Manning et al, '02).
John Blenis-Department of Cell Biology, Harvard Medical School
Tuberous Sclerosis Complex Gene Products, Tuberin and Hamartin,
Control mTOR Signaling by Acting as a GTPase-Activating Protein
Complex toward Rheb (Tee et al, '03).
Elizabeth Petri Henske-Fox Chase Cancer Center
Regulation of B-Raf Kinase Activity by Tuberin and Rheb is mTOR
Independent (Karbowniczek et al '04).
Additional recent TSC pathway articles
TSC2 Mediates Cellular Energy Response to Control Cell Growth & Survival
(Inoki et al, '03)
Drug Screening at TRI
Drug Screening Strategy Employed by TRI 2001
Read more about Libraries of Chemical Compounds
2002
The Science of Large Scale Virtual Screening
2001
The Science of Making Drugs de novo 2002
The Reality of Making Drugs de novo 2002
Literature describing D2OL targets:
PTEN Target 1999
PI3K Target 2000
mTOR/FRAP Target 1997
EIF4E Target 2002
this page last reviewed
|
